Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Parkinsons disease drug Ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial
Mon, 06/05/2023 - 17:04
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson's disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average.
Government has banned 14 FDCs which has no therapeutics justification
Mon, 06/05/2023 - 16:13
Government has banned 14 FDCs after recommendations of the Expert Committee which stated that there is no therapeutic justification for these FDCs and the FDCs may involve risk to human beings.
The Central Government in exercise of the powers conferred by section 26A of the Drugs and Cosmetics act 1940 (23 of 1940) prohibited the manufacture for sale, sale and distribution for human use of 14 drug FDCs (fixed dose combinations).
Cutting breakfast carbs can benefit people with Type 2 diabetes
Thu, 06/01/2023 - 16:25
An international team, led by UBC Okanagan researchers, suggests a simple tweak to the first meal of the day might help people living with Type 2 diabetes (T2D) better control their blood sugar levels.
Scientists unveil RNA-guided mechanisms driving cell fate
Thu, 06/01/2023 - 16:16
The early stages of embryonic development contain many of life’s mysteries. Unlocking these mysteries can help us better understand early development and birth defects, and help develop new regenerative medicine treatments.
Researchers based at the Australian Regenerative Medicine Institute (ARMI) at Monash University have characterised a critical time in mammalian embryonic development using powerful and innovative imaging techniques, with their work published in Nature Communications.
Lupin gets Health Canada approval of Tiotropium Bromide
Sat, 05/27/2023 - 15:37
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
FDA approves sotagliflozin for treatment of Heart Failure
Sat, 05/27/2023 - 15:31
Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with :
heart failure or
type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
New antibodies and vaccine targets discovered against Lassa Virus
Fri, 05/26/2023 - 16:11
Every year, hundreds of thousands of people in West Africa become infected with Lassa virus, which can cause Lassa fever and lead to severe illness, long-term side effects or death. There are currently no widely approved treatments or vaccines for the disease. Now, scientists at Scripps Research have determined the structure of the critical protein complex that lets Lassa virus infect human cells.
Stem cell transplantation can kill HIV, suggests research
Fri, 05/26/2023 - 16:08
New research from Oregon Health & Science University is helping explain why at least five people have become HIV-free after receiving a stem cell transplant. The study’s insights may bring scientists closer to developing what they hope will become a widespread cure for the virus that causes AIDS, which has infected about 38 million people worldwide.
Milvexian of Janssen Pharmaceutical granted U.S. FDA fast track designation
Fri, 05/26/2023 - 16:03
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients.
DCA shuts 11 pharma companies in Himachal Pradesh
Fri, 05/26/2023 - 15:58
The Drug Control Administration (DCA) has stopped 11 pharmaceutical manufacturing firms located in the pharmaceutical hub of Baddi, Barotiwala, Nalagarh, Sirmaur and Kangra districts after significant observations were detected in its functioning during risk-based inspections conducted recently.
State Drugs Controller Navneet Marwaha said, "In the last two months, 29 firms were inspected in the second phase of the joint inspection by the state DCA and the Central Drugs Standard Control Organisation."